# Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

> **NCT00711828** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 21 (actual)

## Conditions studied

- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Nodal Marginal Zone Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Splenic Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT00711828
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2013-11
- **Final completion:** 2018-04-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00711828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00711828, "Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00711828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*